Alio

About Alio

Alio, Inc., formerly known as GraftWorx, is a medical technology company founded in 2012 by David Kuraguntla, Samit Gupta, and Robert Rushenberg. CEO David Kuraguntla's path to founding Alio was shaped by his experiences in the Air Force and medical school, where he identified a need for better technological solutions for managing chronic conditions. Drawing on his background as an NIH researcher and preparing for a surgical residency, he teamed up with co-founder Samit Gupta, a childhood friend with a PhD in biomedical engineering, to create the company.

The company operates in the remote patient monitoring market, focusing on individuals with chronic conditions, particularly those with end-stage kidney disease (ESKD) undergoing dialysis. Alio's business model centers on providing its monitoring platform to clinical sites and healthcare providers, with costs often covered by a patient's insurance. The core of their offering is the Alio Platform, an FDA-cleared system designed to capture and analyze clinical-grade data without invasive procedures. This platform consists of the SmartPatch™, a wearable device worn by the patient; a hub that wirelessly transmits the collected data to the cloud; and a web portal for clinicians.

The SmartPatch is a multi-metric device that monitors key physiological parameters painlessly. Its sensors can measure potassium levels, hemoglobin, hematocrit, skin temperature, and auscultation (the sounds of blood flow). This data is transmitted automatically, requiring no action from the patient, and is analyzed by Alio's proprietary AI-driven algorithms. The system generates actionable notifications for clinical care teams when readings fall outside of predetermined ranges, enabling early intervention to potentially reduce hospitalizations and improve patient outcomes. The platform is designed to supplement, not replace, traditional methods like monthly blood draws, by providing continuous insight into a patient's condition.